Semaglutide, the active ingredient in Wegovy, reduces migraine severity and may lower migraine frequency, with women experiencing greater benefits than men, according to recent research.
A study examining semaglutide's effects on migraine found that patients using the medication reported fewer and less severe headaches. The reduction in migraine burden appeared connected to weight loss, one of semaglutide's primary effects. Women saw more pronounced improvements compared to men taking the same medication.
Semaglutide works by mimicking glucagon-like peptide 1 (GLP-1), a hormone that regulates appetite and blood sugar. The medication has gained popularity for weight management, but researchers increasingly recognize its potential benefits beyond weight loss. Obesity and overweight status correlate with increased migraine frequency and severity, so semaglutide's weight-loss effects may indirectly reduce migraine burden.
The gendered difference in outcomes warrants attention. Women experience migraines at roughly three times the rate of men, partly due to hormonal factors. The greater migraine improvement women reported on semaglutide suggests the medication may interact with migraine biology in ways beyond simple weight reduction, though researchers have not yet identified the exact mechanisms.
For people with migraines considering semaglutide, the findings offer potential dual benefits. Those struggling with weight management and frequent migraines may experience relief on both fronts. However, semaglutide is not approved specifically for migraine treatment. Anyone considering the medication should discuss their migraine history with their healthcare provider, as individual responses vary.
The research adds to emerging evidence that GLP-1 receptor agonists offer benefits extending past their original indications. As more studies examine semaglutide's effects on various conditions, clinicians gain better insight into who might benefit most from treatment. For women with both weight